HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


House Cosmetics Bill Imminent With Small – And Big – Business Support

This article was originally published in The Rose Sheet

Executive Summary

A second bill to enhance FDA's oversight of the cosmetics industry is expected to be introduced in the next few weeks, according to Independent Cosmetic Manufacturers and Distributors President and CEO Pam Busiek. The bill will launch in the House – likely with bipartisan support – and be modeled after 2012's Cosmetic Safety Amendments Act, she said.

You may also be interested in...

In Brief: Alternate Cosmetics Bill Pushed Back; ECHA Finds Unapproved Animal Tests; More

An awaited alternative to the controversial Personal Care Products Safety Act is now expected to emerge after Congress's summer recess, ICMAD President Pam Busiek says. More news in brief.

Editorial: Will Next Anti-Aging Market Disruptor Be Anti-Anti-Aging?

"The Rose Sheet" makes a case for the theoretical Dollar Anti-Aging Club and why updating the FDCA's "cosmetic" definition as part of broader regulatory reform could be in industry's interest.

Feinstein Bill Lacks ‘Crucial’ National Uniformity Assurance – ICMAD

Small-business trade group the Independent Cosmetic Manufacturers and Distributors says the Personal Care Products Safety Act would place an undue burden on small businesses and fails to address national uniformity issues. In an interview with “The Rose Sheet,” ICMAD President and CEO Pam Busiek discussed the group’s opposition to the bill and suggested that 2012’s Cosmetic Safety Amendments Act would have been a better starting point for legislation.

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts